-
Assembly Biosciences NASDAQ:ASMB Assembly Bio is a clinical-stage biotechnology company committed to bringing finite and curative therapies to the 270 million people living with hepatitis B virus (HBV) worldwide. A pioneer in the development of a new class of potent, oral core inhibitor drug candidates, Assembly Bio's approach aims to break the complex viral replication cycle of HBV to free patients from a lifetime of therapy. Assembly Bio's strategy toward cure includes a leading portfolio of more potent, next-generation core inhibitors, proof-of-concept combination studies and a research program focused on the discovery of novel HBV targets.
Location: | Website: www.assemblybio.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-5.627M
Cash
109.2M
Avg Qtr Burn
N/A
Short % of Float
0.46%
Insider Ownership
31.62%
Institutional Own.
18.57%
Qtr Updated
06/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date | |
---|---|---|---|
ABI-5366 Details Genital herpes (HSV), Sexually transmitted infections | No event data in pipeline | | |
ABI-4334 Details Liver infection, Hepatitis B, Liver disease | Phase 1b Data readout | ||
Vebicorvir (VBR, ABI-H0731) Details Liver infection, Chronic liver disease, Hepatitis B | Failed Discontinued | ||
ABI-H2158 Details Liver infection, Liver disease, Hepatitis B | Failed Discontinued | ||
ABI-H3733 Details Liver disease, Hepatitis B, Liver infection | Failed Discontinued |